SCA
XFOR icon

Sassicaia Capital Advisers’s X4 Pharmaceuticals XFOR Stock Holding History

Sassicaia Capital Advisers’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-4,600
Closed -$268K – 31
2023
Q2 		$268K Buy
+4,600
New +$236K 0.23% 24

Other funds holding XFOR

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TLP
Tri Locum Partners New York $713M AUM 68.92% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Sassicaia Capital Advisers's XFOR Position: Q3 2023 in Review

Sassicaia Capital Advisers sold out of X4 Pharmaceuticals (XFOR) in Q3 2023, closing a stake of 4,600 shares — an estimated $268K sold.

Sassicaia Capital Advisers first reported a position in XFOR in Q2 2023 and held it in 1 quarter. The position peaked at $268K in Q2 2023. 91 funds tracked by Wall St. Rank hold XFOR as of Q3 2023.

  • Sassicaia Capital Advisers reported no remaining X4 Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Sassicaia Capital Advisers sold 4,600 X4 Pharmaceuticals shares in Q3 2023, an estimated $268K.
  • Sassicaia Capital Advisers first reported a position in X4 Pharmaceuticals in Q2 2023 and held it in 1 quarter.
  • Sassicaia Capital Advisers's X4 Pharmaceuticals position peaked at $268K in Q2 2023.
  • 91 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q3 2023.

Based on Sassicaia Capital Advisers's 13F filing for Q3 2023, filed 14 Nov 2023.